PsychRounds: The Psychiatry Podcast
by Dr. Tanner Hewitt, Dr. Larry Wang and Dr. Bradley Miller
Is this your podcast?On the show
From 18 epsHosts
Recent guests
Recent episodes
Pharmacogenetic Testing in Psychiatry
Oct 7, 2026
22m 18s
GLP-1 Agonists (Ozempic, Wegovy) in Psychiatry
Sep 16, 2026
32m 53s
Landmark Studies: The STAR*D Trial
Sep 2, 2026
28m 05s
Dogs in Mental Health with Dr. Nancy Gee: A Biopsychosocial Approach
Aug 19, 2026
54m 48s
Centanafadine (Simtriyo): A New Medication for ADHD
Aug 5, 2026
28m 22s
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Based on 1 signal.
Built from
By chart position
- 🇺🇸United States · MedicineHOME#7528K to 150K
- 🇬🇧United Kingdom · Medicine#563.4K to 18K
- 🇵🇹Portugal · Medicine#29778 to 4.1K
- 🇩🇰DK · Medicine#36576 to 3.0K
- 🇿🇦ZA · Medicine#39516 to 2.7K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
37K to 198K🎙 Weekly cadence·117 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
75K to 396K🇺🇸76%🇬🇧9%🇵🇹2%+11 more - Active Followers
Loyal subscribers who consistently listen
41K to 218K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 10/7/26 | Pharmacogenetic Testing in Psychiatry | Welcome back, everyone! We’re back after PRITE, and today we’re discussing pharmacogenetic testing. | 22m 18s | ||||||
| 9/16/26 | GLP-1 Agonists (Ozempic, Wegovy) in Psychiatry | Today, we will discuss GLP-1's and the emerging use of this class of medications in psychiatry.Sources:https://pubmed.ncbi.nlm.nih.gov/42247271/https://pmc.ncbi.nlm.nih.gov/articles/PMC11441540/https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2838205https://pubmed.ncbi.nlm.nih.gov/42070571https://pubmed.ncbi.nlm.nih.gov/41806782/ | 32m 53s | ||||||
| 9/2/26 | Major Depressive DisorderSTAR*D trial+3 | — | STAR*D | — | STAR*DMajor Depressive Disorder+3 | — | 28m 05s | ||
| 8/19/26 | dogsmental health+4 | Dr. Nancy Gee | VCUDogs Supporting Human Health and Well-Being: A Biopsychosocial Approach+1 | — | dogsmental health+5 | — | 54m 48s | ||
| 8/5/26 | ADHDmedication+3 | — | CentanafadineSimtriyo+1 | — | CentanafadineSimtriyo+5 | — | 28m 22s | ||
| 7/22/26 | seminal studiespsychiatry+3 | — | CATIE Trial | — | CATIE Trialpsychiatry+3 | — | 21m 53s | ||
| 7/8/26 | recreational drug useKratom+3 | — | Kratom | — | Kratomrecreational use+3 | — | 21m 13s | ||
| 6/3/26 | Modafinilpsychiatry+4 | — | ModafinilTeva Pharmaceuticals USA, Inc.+5 | — | ModafinilProvigil+5 | — | 19m 36s | ||
| 5/20/26 | medicationpsychiatry+3 | — | NaltrexoneNCBI+2 | — | Naltrexonepsychiatry+3 | — | 16m 10s | ||
| 5/6/26 | placebo effectpsychiatry+3 | — | PubMedNCBI+2 | — | placebo effectpsychiatry+3 | — | 22m 14s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/8/26 | Amantadinepsychiatry+3 | — | AmantadineSymmetrel | — | AmantadineSymmetrel+3 | — | 17m 01s | ||
| 3/21/26 | tardive dyskinesiaVMAT2 inhibitors+3 | — | Valbenazine (Ingrezza)Deutetrabenazine (Austedo)+3 | — | tardive dyskinesiaVMAT2 inhibitors+3 | — | 17m 19s | ||
| 2/25/26 | DSMPsychiatry+3 | Dr. Allen Frances | DSM IIIDSM IV | — | DSMAllen Frances+3 | — | 55m 50s | ||
| 1/28/26 | psychiatrymedication+3 | — | TopiramateTopamax+2 | — | TopiramateTopamax+3 | — | 15m 19s | ||
| 1/14/26 | psychiatric illnesspsychotherapy+3 | Dr. Mark Ruffalo | University of Central Florida College of MedicineTufts University School of Medicine+2 | — | psychiatric illnesspsychotherapy+3 | — | 54m 32s | ||
| 12/31/25 | benzodiazepinepsychiatry+3 | — | LorazepamAtivan+3 | — | LorazepamAtivan+5 | — | 14m 27s | ||
| 12/17/25 | iron deficiencymental health+3 | — | NCBIScienceDirect+3 | — | iron deficiencypsychiatry+4 | — | 25m 24s | ||
| 12/3/25 | Nutritional PsychiatryMental Health+3 | Dr. Laura Lachance | EASe-GAD trialAntidepressant Food Score+1 | — | Nutritional PsychiatryAntidepressant Food Score+4 | — | 49m 18s | ||
| 11/19/25 | stressculture+3 | Dr. Robert Sapolsky | Stanford UniversityInstitute of Primate Research+3 | — | stressculture+5 | — | 1h 03m 08s | ||
| 11/5/25 | SSRIsmental health+3 | — | Selective Serotonin Reuptake Inhibitors | — | SSRIsSelective Serotonin Reuptake Inhibitors+3 | — | 32m 53s | ||
| 10/29/25 | Alprazolam (Xanax) | Welcome back! Today we have a very special episode on Alprazolam, brand-name Xanax. This benzodiazepine is one of the most commonly-prescribed and sought out psychotropic medications. https://www.ncbi.nlm.nih.gov/books/NBK538165/https://pmc.ncbi.nlm.nih.gov/articles/PMC6769182/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5846112/https://pubmed.ncbi.nlm.nih.gov/6141930/https://pubmed.ncbi.nlm.nih.gov/17514187/ | 15m 00s | ||||||
| 10/22/25 | Climate Change and Mental Health with Dr. Ferdnand Osuagwu | Join us today for an episode on the impact of climate change on mental health. We'll be exploring concepts like eco-anxiety, advocacy, the impact of nuclear war and practical tips. We're joined by guest Dr. Ferdnand Osuagwu, who was the former Chair of the Caucus on Climate Change and Mental Health of the American Psychiatric Association (APA) and founder of the Ferdnand Foundation International, an organization dedicated to underserved and marginalized populations and with a particular emphasis on addressing their needs in the areas of health, education, climate change, social justice and resource mobilization. Ferdnand Foundation Website: https://ferdnandfoundation.org/Ferdnand Foundation Youtube Channel: https://www.youtube.com/@FerdnandFoundation/featured | 34m 58s | ||||||
| 10/15/25 | Introduction to Benzodiazepines | Today, we are talking about a very popular, yet controversial class of medications - the Benzodiazepines . Let's look at their mechanism of action, clinical indications, pharmacology, risks, withdrawal syndromes, and prescribing guidance. And of course, we'll be tackling the question: what are the risks and benefits of long-term use? References: https://pubmed.ncbi.nlm.nih.gov/30098211/https://pubmed.ncbi.nlm.nih.gov/32252539/https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rateshttps://aapp.org/guideline/benzohttps://pubmed.ncbi.nlm.nih.gov/40526204/https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/https://www.ncbi.nlm.nih.gov/books/NBK470159/https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment/article/benzodiazepines-for-anxiety-disorders-maximising-the-benefits-and-minimising-the-risks/43A366723CD1B3616BAB08F69FF65A88 | 22m 12s | ||||||
| 10/8/25 | Introduction to Anxiety Disorders | Welcome to an introductory episode on anxiety disorders as requested by a long-time listener. References:https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/https://pmc.ncbi.nlm.nih.gov/articles/PMC5573565/https://deepblue.lib.umich.edu/bitstream/handle/2027.42/175862/Nesse%20Anxiety%20Disorders%20in%20Evolutionary%20Perspective%202022.pdf?sequence=1 | 25m 48s | ||||||
| 10/1/25 | Loxapine (Loxitane) Revisited with Dr. Jonathan Meyer | Join us as we talk about Loxapine, an older medication that’s stood the test of time and found a niche in psychiatric practice. This is a revision of an earlier episode, after Dr. Bradley Miller chatted with Dr. Jonathan Meyer at the 2025 APA Conference. Dr. Meyer joins us at the beginning to provide an addendum to the original episode. | 24m 08s | ||||||
Showing 25 of 117
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Psychopharmacology and Psychiatry Updates
Psychopharmacology Institute
Psychiatry Boot Camp
Mark Mullen, MD
The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast
NEI Podcast
Neuroscience Education Institute
Psychiatry & Psychotherapy Podcast
David Puder, M.D.
Psychofarm Podcast
Psychiatry, Skepticism, and Integration.
Back from the Abyss: Psychiatry in Stories | Psychotherapy, Trauma, and Psychedelics
Craig Heacock MD
Chart history for PsychRounds: The Psychiatry Podcast
Peaked at #29 in PT, currently #29 in PT.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| PT | — | #29 | #29 | — |
| Denmark | — | #36 | #36 | — |
| CZ | — | #37 | #37 | — |
| South Africa | — | #39 | #39 | — |
| CL | — | #40 | #40 | — |
| PE | — | #43 | #43 | — |
| HK | — | #45 | #45 | — |
| Norway | — | #53 | #53 | — |
| United Kingdom | — | #56 | #56 | — |
| IL | — | #57 | #57 | — |
| KE | — | #58 | #58 | — |
| PL | — | #67 | #67 | — |
| United States | — | #75 | #75 | — |
| GR | — | #85 | #85 | — |
| SA | — | #114 | #114 | — |
| RO | — | #128 | #128 | — |
| India | — | #136 | #136 | — |
| Italy | — | #144 | #144 | — |
| South Korea | — | #151 | #151 | — |
| PT | — | #157 | #157 | — |
Chart Positions
24 placements across 23 markets.
Chart Positions
24 placements across 23 markets.